FDA rais­es safe­ty ques­tions with GSK's po­ten­tial CKD drug ahead of ad­comm

The FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee to­mor­row will vote on whether the ben­e­fits of GSK’s dapro­du­s­tat, an oral hy­pox­ia-in­ducible fac­tor-pro­lyl hy­drox­y­lase in­hibitor, out­weighs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER